Schedule 13G ownership disclosure

REIN THERAPEUTICS INC

Common Stock, $0.001 par value · CUSIP: 00887A204

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Voss Value Master Fund, LP

    Shares: 926,441.00 · Class: 3.5%

  • Voss Value-Oriented Special Situations Fund, LP

    Shares: 500,000.00 · Class: 1.9%

  • Voss Advisors GP, LLC

    Shares: 1,426,441.00 · Class: 5.4%

  • Voss Capital, LP

    Shares: 4,468,969.00 · Class: 17.0%

  • Cocke Travis W.

    Shares: 4,468,969.00 · Class: 17.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-26-000365
Form type
SCHEDULE 13G/A
Filer
Rein Therapeutics, Inc.
CIK
CIK 1420565
Filed
Feb 13, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub